AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Read more here.

Exosome Market for Cosmetic Applications is projected to reach USD 26.6 Bn by 2035, expanding at a CAGR of 27.4% from 2025 to ...

The Korean government has nearly quadrupled its investment in the biological big data sector over the past few years as part of an initiative to ...

Biotech and pharma greenhouse gas emissions are falling – but is current progress fast enough? Discover My Green Lab’s Impact ...

In case you haven't guessed it already, the big thing to wait on before buying any shares of Summit Therapeutics is the FDA's ...

Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy, challenger from Massachusetts biotech Dyne ...

As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, ...

Most AI drug development is fueled by foundation models in biology—models that are trained on vast biological data sets and ...

In the evolving landscape of artificial intelligence (AI), the assumption that more data lead to better models has driven unchecked reliance on synthetic data to augment training datasets. Although ...

A major but underappreciated driver of recent blockchain momentum has been the accelerating convergence between blockchain ...

Retail investors are understandably on edge after several sessions of market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says ...

Ming Yu was set up in 2018 by Cao Guoqing, a biochemist with an international profile in cutting-edge drug research. Cao ...